ProsTAV, a clinically useful test in prostate cancer: an extension ...

ProsTAV could contribute to MRI in the current diagnoses' pathway of PCa, and this possibility needs to be further explored in future ampler prospective trials. Acknowledgements. The authors thank Enrique Segovia and Nuria de Pedro (Life Length S. L.) for collaborating on this study. María Romero Olleros (Trialance SCCL) provided medical ...

PDF ProsTAV,anovelblood basedtestforbiopsydecision ...

CI, 0.83-0.99). ProsTAV® would make it possible to avoid 33% of biopsies. Conclusions: ProsTAV®, a predictive model based on telomere analysis throughTAV, could be used to increase the prediction capacity of significant PCa in patients with PSA between 3 and 10ng/mL. KEYWORDS biopsy, predictive model, prostate cancer, telomere

ProsTAV, a novel blood-based test for biopsy decision management in ...

ProsTAV® was developed by multivariate logistics regression based on three clinical variables and six TAVs. The predictive capacity and accuracy of ProsTAV® were summarized by receiver operating characteristic (ROC) curves and its clinical benefit with decision curves analysis. Results: Telomeres from 1043 patients were analyzed.

ProsTAV, a novel blood‐based test for biopsy decision management in ...

ProsTAV®, a predictive model based on telomere analysis through TAV, could be used to increase the prediction capacity of significant PCa in patients with PSA between 3 and 10 ng/mL. CONFLICT OF INTEREST STATEMENT. EGG has received funding for research from Ferrer, Opko, and Life Length. LF and NdP are current employees of Life Length.

ProsTAV, a novel blood-based test for biopsy decision ... - PubMed

ProsTAV® was developed by multivariate logistics regression based on three clinical variables and six TAVs. The predictive capacity and accuracy of ProsTAV® were summarized by receiver operating characteristic (ROC) curves and its clinical benefit with decision curves analysis. Results: Telomeres from 1043 patients were analyzed. The median ...

PDF ProsTAV, a clinically useful test in prostate cancer: an ... - Springer

ProsTAV is a risk estimation test based on algorithm-derived models that use TAV as a biomarker diagnosing PCa (also called "risk score") based on a refined model. Data derives from telomeric measurements and the patient's clin - ical history to indicate whether the individual is at low risk

Prostate Cancer | ProsTAV, a clinically useful test in prostate cancer ...

ProsTAV could have reduced the biopsies performed by 27% and showed some initial evidence of a putative benefit in the diagnosis pathway combined with MRI. Conclusions ProsTAV increases the prediction capacity of significant PCa in patients with PSA between 3 and 10 ng/ml and could be considered a complementary tool to improve the patient ...